Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update [Yahoo! Finance]
Tharimmune, Inc. (THAR)
Company Research
Source: Yahoo! Finance
initiate a Phase 2 study of its lead asset, TH104, in patients with moderate-to-severe pruritus associated with primary biliary cholangitis (PBC), a rare and chronic liver disease. The study, expected to launch in 2025, will assess the safety, tolerability, and efficacy of TH104 in reducing itch in PBC patients. The company also provided a business update, highlighting its progress in manufacturing, clinical and regulatory areas, as well as its expansion of its Board of Directors and licensing agreements. Tharimmune's CEO expressed enthusiasm for the advancement of TH104 into Phase 2, citing favorable data from previous studies and the potential to address the debilitating effects of chronic pruritus. Generated by Yahoo Finance AI Yahoo Finance used generative AI to summarize key information from this article. Some details may be inaccurate. We take that seriously. Reporting mistakes helps us improve these summaries. Was this helpful? Yes No BRIDGEWATER, NJ / ACCESSWIRE /
Show less
Read more
Impact Snapshot
Event Time:
THAR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THAR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THAR alerts
High impacting Tharimmune, Inc. news events
Weekly update
A roundup of the hottest topics
THAR
News
- Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business UpdateAccesswire
- Tharimmune, Inc. (NASDAQ: THAR) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs [Yahoo! Finance]Yahoo! Finance
- Tharimmune Announces $2.02 Million Private Placement to Advance Development ProgramsAccesswire
- Tharimmune, Inc. (NASDAQ: THAR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
THAR
Sec Filings
- 12/30/24 - Form 424B3
- 12/27/24 - Form EFFECT
- 12/20/24 - Form 4
- THAR's page on the SEC website